Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

A scientific statement has been published by the American Heart Association regarding the effect of sleep health on cardiometabolic health.

The FDA is reviewing the BLA for clesrovimab to prevent respiratory syncytial virus (RSV) disease in infants during their first RSV season. Clesrovimab is an extended half-life RSV fusion glycoprotein ...